3rd December 2024
18th November 2024
MPM BioImpact-Founded Company, Syndax, Announces FDA Approval of Revuforj® (revumenib)
14th November 2024
Dr. Michael Ehlers Joins MPM BioImpact as Entrepreneur Partner – Endpoints News
14th November 2024
Michael Ehlers, M.D., Ph.D., Experienced R&D Leader and Accomplished Biotechnology Executive, Appointed as MPM BioImpact Entrepreneur Partner
7th May 2024
Ivan Cheung, CEO of NextPoint Therapeutics, Named to TIME Magazine’s Top 100 Most Influential People in Global Health
11th April 2024
MPM BioImpact Appoints Frank Neumann, M.D., Ph.D., Distinguished Expert in Clinical Development, as Entrepreneur Partner
26th February 2024
WSJ: Investors Flock Back to Biotech After a Long, Cold Spell – Featuring Chris Bardon
2nd January 2024
What VCs Look for When Investing – BioSpace Podcast featuring Ansbert Gadicke
15th December 2023
What VCs Really Think of the Market – BioSpace Podcast featuring Ansbert Gadicke
13th October 2023